This afternoon.

Further to yesterday’s Astrazeneca/EU shenanigans

…and with the Anglo/Swedish pharma giant having denied claims that its’ vaccine was substantially less effective among the over-65s…

…via AP:

A draft recommendation from Germany’s vaccination advisory committee calls for offering the AstraZeneca vaccine only to people aged 18-64 for now, citing what it says is insufficient data to judge its effectiveness for older people.

The European Medicines Agency is expected to approve the AstraZeneca vaccine for use in the 27-nation European Union on Friday.

…Germany’s permanent vaccination commission said that “there currently is not sufficient data to assess the vaccination effectiveness from 65 years.”

German draft doesn’t recommend AstraZeneca jab for over-65s (WBNG)

Yesterday: Vial Behaviour

Earlier: Zero Sum Game

Sponsored Link

18 thoughts on “Non-Vintage

  1. Chevy Chase

    Where’s that Bertie Wooster fella on here who normally posts about Brexit and never answers anyone? He should have the inside line on these Oxford chaps.

    Reply
    1. theofficepest

      its more effective to get the virus and die is it

      anyway, that is some daily sport like news outlet you have there

      so they balsed up there vaccine is? good work lads

      Reply
      1. ce

        I think Broadsheet should have an “on this day in ‘insert year’ in the Daily Sport” section with the nightly paper preview

        Today, Yesteryear, Tonight

        Reply
      2. Crocodile Dundalk

        “its more effective to get the virus and die is it”

        Who says you’re gonna die!?

        “anyway, that is some daily sport like news outlet you have there”

        Struggling for a legitimate counter, gives up, plays man instead of ball.

        “so they balsed up there vaccine is? good work lads”

        Lmao

        Reply
      1. V aka Frilly Keane

        well tis how Pharma R+D works

        If the targeted specific outcome research doesn’t look like it will convert into a product that can go into production, and into market,
        Then R+D costs etc can’t be capitalised
        So as soon as they are aware they’re on a loser they bail
        and the expenditure is immediately written off (that means against current period profits)

        Nothing to stop them from going back to the drawing board and taking the same ideal outcome in a different research etc direction
        but the same rules apply

        Some of the Pharma Insider lads can be more specific on how strict Research costs are managed, treated in the accounts etc
        But I imagine tis very organised, monitored and down to a single cent allocated and treated correctly in their Management Accounts

        Reply
    2. Charlie

      Probably the most ridiculous thing I’ve read today. Congratulations, you’ll be a celebrity down outside the GPO next weekend.

      Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Sponsored Link
Broadsheet.ie